Data presented at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that testing individuals at risk may be beneficial.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint.

Bristol-Myers Squibb Company (NYSE: BMY) announced double-digit sales growth in a quarter that was highlighted by important new product approvals in both the U.S. and Europe, and key data from the Company's cardiovascular, oncology and diabetes franchises.

The National Comprehensive Cancer Network® (NCCN®) announces the development of the first continuing medical education (CME) program to leverage data in the NCCN Oncology Outcomes Database (NCCN Database) to objectively measure the impact of comprehensive performance improvement on patient outcomes.

Pfizer Inc. (NYSE: PFE) today reported financial results for second-quarter 2011. Second-quarter 2011 revenues were $17.0 billion, a decrease of 1% compared with the year-ago quarter.

Sanofi's total sales grew 6.9% to €8,349 million. Excluding Genzyme, sales were down 4.0% reflecting €778 million of sales lost due to generic competition vs. Q2 2010. Growth platforms grew by 9.5% and including Genzyme accounted for 65.2% of total sales.

Sales of the Bayer Group grew by 0.8 percent in the second quarter to EUR 9,252 million (Q2 2010: EUR 9,179 million). The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 5.4 percent. Business performance in the emerging markets made an above-average contribution to this development.